Metastatic basal cell carcinoma: Complete response to chemotherapy and associated pure red cell aplasia

Benedito Carneiro, William Watkin, Uday Mehta, Bruce Brockstein*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Basal cell carcinoma (BCC) is usually a benign and indolent cancer cured in greater than 95 percent of cases. Nevertheless, it can be locally destructive or occasionally metastasize to distant organs. We report a case of BCC metastatic to the lungs, occurring 17 years after the primary BCC was noticed, that responded to carboplatin and paclitaxel on 3 occasions. The patient also developed pure red cell aplasia (PRCA). Work-up did not reveal underlying thymoma or infectious, rheumatologic, or lymphoproliferative disorders. Parvovirus serologies were negative, and antibodies against erythropoetin were not detected. There was no history of exposure to drugs associated with PRCA. Bone marrow biopsy on 2 different occasions did not show evidence of myelodysplasia. PRCA may represent an unusual paraneoplastic syndrome associated with BCC as reported with other carcinomas. This is the first report of PRCA associated with metastatic BCC or the drugs carboplatin and paclitaxel, which were used to treat it. The literature on chemotherapy for metastatic BCC is reviewed.

Original languageEnglish (US)
Pages (from-to)396-400
Number of pages5
JournalCancer Investigation
Issue number4
StatePublished - Jun 1 2006


  • Carboplatin
  • Chemotherapy
  • Lung metastases
  • Metastatic basal cell carcinoma
  • Paclitaxel
  • Pure red cell aplasia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Metastatic basal cell carcinoma: Complete response to chemotherapy and associated pure red cell aplasia'. Together they form a unique fingerprint.

Cite this